|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Iteos Therapeutics, Inc. (ITOS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
37,960,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile iTeos Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of a differentiated immuno-oncology therapeutics for patients. Co.'s product candidate, inupadenant, is designed as a selective small molecule antagonist of the adenosine A2a receptor, in the adenosine pathway, a main driver of immunosuppression in the tumor microenvironment across a range of tumors. Co.'s main antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains, an immune checkpoint with multiple mechanisms of action leading to immunosuppression.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,000 |
5,000 |
Total Buy Value |
$0 |
$0 |
$41,850 |
$41,850 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
350,000 |
350,000 |
Total Sell Value |
$0 |
$0 |
$5,692,673 |
$5,692,673 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Detheux Michel |
Chief Executive Officer |
|
2022-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
44,700 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-03-11 |
4 |
S |
$36.01 |
$126,035 |
D/D |
(3,500) |
0 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-03-11 |
4 |
OE |
$4.30 |
$15,050 |
D/D |
3,500 |
3,500 |
|
- |
|
Mcgrath Yvonne |
Chief Scientific Officer |
|
2022-03-01 |
4 |
S |
$36.76 |
$367,570 |
D/D |
(10,000) |
0 |
|
- |
|
Mcgrath Yvonne |
Chief Scientific Officer |
|
2022-03-01 |
4 |
OE |
$4.24 |
$42,400 |
D/D |
10,000 |
10,000 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2022-02-23 |
4 |
AS |
$34.30 |
$497,905 |
D/D |
(14,500) |
34,700 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-02-11 |
4 |
AS |
$35.52 |
$125,459 |
D/D |
(3,500) |
0 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-02-11 |
4 |
OE |
$4.30 |
$15,050 |
D/D |
3,500 |
3,500 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2022-01-25 |
4 |
AS |
$35.45 |
$517,378 |
D/D |
(14,500) |
49,200 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-01-14 |
4 |
AS |
$39.25 |
$137,614 |
D/D |
(3,500) |
0 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-01-14 |
4 |
OE |
$4.30 |
$15,050 |
D/D |
3,500 |
3,500 |
|
- |
|
Oncology Impact Fund (cayman) Management L.p. |
10% Owner |
|
2022-01-05 |
4 |
S |
$42.03 |
$1,275,484 |
I/I |
(30,347) |
4,484,728 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2022-01-05 |
4 |
S |
$42.03 |
$762,214 |
I/I |
(18,135) |
2,738,785 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2022-01-05 |
4 |
S |
$42.03 |
$762,214 |
I/I |
(18,135) |
2,738,785 |
|
- |
|
Oncology Impact Fund (cayman) Management L.p. |
10% Owner |
|
2022-01-04 |
4 |
S |
$42.05 |
$9,176,850 |
I/I |
(215,122) |
4,515,075 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2022-01-04 |
4 |
S |
$42.05 |
$5,483,836 |
I/I |
(128,550) |
2,756,920 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2022-01-04 |
4 |
S |
$42.05 |
$5,483,836 |
I/I |
(128,550) |
2,756,920 |
|
- |
|
Davis Aaron I. |
Director |
|
2022-01-04 |
4 |
S |
$41.84 |
$7,898,264 |
D/D |
(184,677) |
0 |
|
- |
|
Davis Aaron I. |
Director |
|
2022-01-03 |
4 |
S |
$47.63 |
$24,677,379 |
D/D |
(515,323) |
46,477 |
|
- |
|
Biniszkiewicz Detlev |
Director |
|
2022-01-03 |
4 |
AS |
$51.90 |
$181,650 |
D/D |
(3,500) |
0 |
|
- |
|
Biniszkiewicz Detlev |
Director |
|
2022-01-03 |
4 |
OE |
$19.00 |
$66,500 |
D/D |
3,500 |
3,500 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-01-03 |
4 |
AS |
$51.90 |
$363,300 |
D/D |
(7,000) |
0 |
|
- |
|
Lager Joanne Jenkins |
Chief Medical Officer |
|
2022-01-03 |
4 |
OE |
$4.30 |
$30,100 |
D/D |
7,000 |
7,000 |
|
- |
|
Gall Matthew |
Chief Financial Officer |
|
2021-12-27 |
4 |
S |
$46.45 |
$232,250 |
D/D |
(5,000) |
14,429 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-12-22 |
4 |
AS |
$44.31 |
$727,888 |
D/D |
(16,163) |
63,700 |
|
- |
|
229 Records found
|
|
Page 2 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|